Comparative Pharmacology
Head-to-head clinical analysis: PARAFLEX versus SOMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARAFLEX versus SOMA.
PARAFLEX vs SOMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
250 mg to 350 mg orally three times daily and at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
Clinical Note
moderateSomatostatin + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin."
Clinical Note
moderateSomatostatin + Methylphenobarbital
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Methylphenobarbital."
Clinical Note
moderateSomatostatin + Hexobarbital
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Hexobarbital."
Clinical Note
moderate1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Somatostatin + Thiamylal
"The risk or severity of adverse effects can be increased when Somatostatin is combined with Thiamylal."